What Algifor Treats: Main Uses and Benefits

Algifor is relevant when supportive symptom management is appropriate for the relief of mild to moderate pain and symptoms associated with heightened physiological activity. This medication is commonly used to help with minor aches and pains. It is primarily applied across three domains: easing pain (analgesia), reducing inflammation, and lowering fever.

It is used in situations involving certain distressing symptoms such as headache, acute toothache, and recurrent menstrual cramps (primary dysmenorrhea). It generally helps address symptom clusters related to inflammatory states, including swelling, stiffness, and joint pain, associated with conditions involving inflammatory or irritative processes. When symptoms become temporarily overwhelming, Algifor assists in reducing elevated body temperature (fever) associated with the common cold, flu, or post-vaccination reactions. This provides support that helps ease the overall symptom burden and supports general well-being during symptomatic phases.

This medication is commonly used to help with minor aches and pains and to reduce fever in both adults and children.

Quick Fact: Relief for Pain
Symptom Domains	Pain, Inflammation, and Fever
Common Conditions	Headache, Toothache, Menstrual Cramps
Key Benefit	May assist with symptom management and comfort

Regulatory References

1. NIH MedlinePlus Drug Information overview

Official Eligibility and Non-Eligibility for Algifor (Ibuprofen)

Official regulatory documents define strict criteria for who is eligible to use Algifor, based on pre-existing conditions, age, and physiological status.

Eligibility Classification	Status/Example	Restriction Detail
Contraindicated Populations	Severe heart failure (NYHA Class IV)	Absolute prohibition against use [1.1].
	Active or recurrent peptic ulcer/GI hemorrhage	Absolute prohibition against use [1.1].
	Third trimester of pregnancy (after ge 20 weeks)	Absolute prohibition due to fetal risk [2.6].
Age-Related Rules	Infants under 3 months of age	Use is generally not recommended or established [3.7].
	Older Adults (ge 60 or ge 65 years)	Use requires careful consideration due to increased risk of serious GI and renal effects [1.5, 1.6].
Condition-Specific Rules	Severe renal or hepatic insufficiency	Absolute prohibition against use [1.1].
	Asthma/Aspirin-sensitive reactions	Contraindicated if prior hypersensitivity to NSAIDs [1.1, 1.4].

Pregnancy and Lactation Eligibility: Use is strictly contraindicated during the third trimester of pregnancy [2.6]. Use is generally not recommended in the first and second trimesters unless the expected benefit justifies the risk [2.4]. Ibuprofen is generally considered compatible with short-term, low-dose use during breastfeeding [1.2, 1.6].

Connection to the overall eligibility profile: Regulatory agencies establish this clear eligibility framework by prohibiting the medicine for populations with severe organ impairment or specific histories (Contraindications), while limiting its use or requiring caution for groups with moderate risk or specific age/pregnancy statuses (Restricted Use) [1.1, 1.5].

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Algifor (Ibuprofen) based on governmental regulatory sources.

Interaction Scope

Category	Description
Specific Interacting Medicines	Lithium, Methotrexate, Warfarin, low-dose Aspirin, Cardiac Glycosides, Zidovudine, Ciclosporin.
Product Categories	Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Anticoagulants, Corticosteroids (Steroid drugs), Antihypertensives (ACE inhibitors, Diuretics), and SSRIs.

Interaction-Related Restrictions

Co-administration is formally contraindicated with other products containing Ibuprofen or other NSAIDs due to an officially documented, significantly increased risk of serious gastrointestinal events.

Official Interaction Statements

• Ibuprofen exhibits a pharmacokinetic interaction that reduces the renal clearance and may increase the plasma concentration of substances such as Lithium and Methotrexate.
• A pharmacodynamic interaction exists with anticoagulants like Warfarin, enhancing their effect and raising the risk of severe hemorrhage.
• Concomitant use with anti-hypertensives may reduce the intended efficacy of those blood pressure medications.
• For patients taking low-dose, immediate-release Aspirin for cardioprotection, the FDA advises a mandatory timing separation: Ibuprofen should be taken at least 8 hours before or at least 30 minutes after the aspirin dose to minimize interference with the antiplatelet effect.
• Habitual consumption of three or more alcoholic drinks daily is officially noted to increase the chance of severe stomach bleeding. The risk of gastrointestinal toxicity is also higher in the older age population.

Connection to the overall interaction profile (2–4 sentences): Regulatory documents define the interaction profile through two primary domains: pharmacokinetic effects leading to reduced clearance and exposure modification of specific co-administered drugs, and pharmacodynamic effects resulting in additive risks, such as increased gastrointestinal bleeding or interference with antiplatelet activity. This structure dictates formal constraints, including contraindicated combinations and timing separation rules.

How Algifor Works

Algifor (ibuprofen) functions as a non-selective, reversible inhibitor of the cyclooxygenase (COX) enzyme system (specifically COX-1 and COX-2). This enzyme inhibition directly targets the initial steps of the arachidonic acid pathway, preventing the conversion of arachidonic acid into key bioactive lipid mediators known as prostanoids.

Reduced prostanoid synthesis, particularly prostaglandin E2 (PGE2), initiates a downstream cascade of diminished signaling. At the intracellular level, this molecular blockade dampens signal transduction sequences that are typically amplified during cellular activation.

This modification results in system-level physiological modulation: decreased PGE2 production in the hypothalamus contributes to adjusting the elevated core temperature set-point, thereby promoting heat loss. Furthermore, reduced availability of pro-sensitizing prostanoids at peripheral sites attenuates the sensitization state of nociceptors, modulating afferent neural input.

How Algifor is Used (Dosing and Administration)

Algifor (Ibuprofen) is an orally administered medication used for symptomatic relief, with its administration governed by product specifications. The guiding principle for its use is to employ the lowest effective dose for the shortest duration necessary to manage symptoms.

---

Official Routes and Administration Details

The approved route of administration for Algifor is oral, available in forms such as tablets, capsules, and oral liquid suspensions. For tablets or capsules, the dose is swallowed whole with water. Oral suspensions must be shaken well and measured using a calibrated device before ingestion.

Administration is generally recommended with food or milk for individuals with a sensitive stomach, although this may slightly delay the onset of action.

---

Standard Dosing Regimens and Frequency

Population	Single Dose Range	Minimum Dosing Interval	Maximum Daily Dose (Short-Term)
Adults (ge 12 yrs)	200 mg to 400 mg	4 to 6 hours	1200 mg

Standard adult dosing for short-term, non-prescription use begins at 200 mg to 400 mg, repeatable after a minimum of 4 to 6 hours, not to exceed 1200 mg in a 24-hour period. Higher daily doses are reserved for specific chronic conditions under direct medical supervision.

Use Duration and Specific Populations

Treatment duration should be limited: do not use for more than 3 days for fever or 3 to 10 days for pain without consulting a healthcare professional. Pediatric dosing relies on body weight (mg/ kg) calculation using the oral suspension. For older adults and those with mild-to-moderate renal or hepatic impairment, the lowest effective dose should be maintained.

Research evidence / Overview of studies for Algifor

Evidence for Use in Acute Pain Relief

Research explored Algifor in contexts involving conditions characterized by fluctuating or episodic manifestations. Studies conducted during periods of increased symptom activity have primarily focused on outcomes related to physical discomfort. These investigations monitored the patient-reported experiences regarding episodic or acute changes over defined time intervals.

Data show patterns related to temporary changes in patient-reported outcomes describing perceived discomfort. Findings indicate that short-term changes were measured, and research highlighted measured short-term changes, contributing to the understanding of how patients reported their experience during these episodes. While these trials provide insight, results apply only to the populations studied in the research.

---

Evidence for Use in Symptomatic Fever Reduction

Algifor was evaluated in research contexts involving fluctuating or unstable symptoms, particularly for conditions linked to inflammatory or irritative states. Research examined temporary physiological imbalance over short-term time frames.

Studies monitored measured changes in outcomes related to systemic or functional imbalance during the study period. The evidence contributes to understanding symptom patterns, reporting changes measured while symptoms became more noticeable.

---

Evidence for Use in Pain Associated with Primary Dysmenorrhea

Research explored Algifor in conditions marked by functional limitations and associated with acute or disruptive episodes. The studies monitored symptom intensity or variability, relevant in trials assessing short-term or episodic symptom patterns and research focused on phases of heightened symptom activity.

Data show patterns related to how patients reported perceived discomfort linked to these episodes. The research reports changes measured during the study period, suggesting that the studies monitored measured changes in outcomes related to daily functioning or activity level in the short term. Findings help contextualize how patients reported their experience during cycles of stability and flare-ups.

---

Long-Term Follow-up and Durability of Evidence

The regulatory and scientific literature describes evidence derived predominantly from acute, short-term administration. The research structure provides limited insight into long-term functional outcomes or effects on quality of life beyond the immediate, acute symptom episode. Extended-duration data or evidence characterizing the durability of response over many months or years is not currently well-established in the research record for these common uses.

---

Evidence in Special Populations

Studies have specifically investigated outcomes in key subgroups, particularly pediatric populations (infants over six months and children). For fever reduction, research has monitored outcomes related to temperature change and duration of effect across these younger age groups. Data for certain other groups, such as those with specific comorbidities, remain more limited, and certainty remains low regarding outcomes in these populations.

---

What is Still Uncertain About the Research Base

The evidence highlights several areas where the research remains limited or inconsistent. Follow-up durations were restricted in many studies, meaning long-term effects are not fully established for repeated use. Data for certain populations remain insufficient, and comparative evidence is lacking against all other available approaches for certain indications. The findings were mixed in some studies, and research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Key Studies & References

1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) - StatPearls

Common questions about Algifor (FAQ)

---

Q: What is the difference between Algifor and other common pain relievers?

A: Algifor's active substance, ibuprofen, is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Official information indicates that this class of medicine not only reduces pain and fever but also actively works to lessen inflammation.

Other common pain relievers, such as paracetamol (acetaminophen), primarily affect pain and fever mechanisms in the central nervous system and do not have a strong anti-inflammatory component.

Q: How quickly does Algifor start working?

A: According to official product information, following oral administration, the onset of pain relief is typically reported to occur within approximately 30 minutes. This is based on studies monitoring how quickly the medicine is absorbed into the body.

Q: How long do the effects of Algifor usually last?

A: The drug is formulated for symptomatic relief that typically lasts for 4 to 6 hours. This duration of effect establishes the minimum recommended interval for when another dose may be taken.

Q: Does Algifor interact with alcohol?

A: Official labeling states that the consumption of alcohol is noted to increase the documented risk of serious gastrointestinal bleeding when used with Algifor.

Q: What happens if I take Algifor and blood pressure medicine?

A: Regulatory documents describe a known interaction with certain blood pressure medications, such as diuretics and ACE inhibitors. This interaction may reduce the intended blood pressure-lowering efficacy of those medications.

Q: Can pregnant women use Algifor?

A: Official guidance states that use is strictly avoided and contraindicated during the third trimester of pregnancy, particularly after 20 weeks gestation, due to documented risks to the fetus. Use in the first and second trimesters is generally not recommended.

Q: Is Algifor suitable for children?

A: The medicine is established for use in children from 3 months of age, usually in the oral liquid suspension form. However, administration to infants between 3 and 12 months of age is subject to specific regulatory conditions and generally requires the direction of a healthcare professional.

Q: Can Algifor be used long-term?

A: The drug is intended for short-term symptomatic relief. Official guidelines typically limit use to not more than 3 days for fever and not more than 10 days for pain, unless the duration is extended under the direction of a healthcare professional.

Q: Does Algifor interact with blood thinners?

A: Yes, regulatory documents describe an interaction with anticoagulants, which are commonly referred to as blood thinners. This interaction may significantly enhance the effect of the blood thinner, thereby increasing the documented risk of bleeding or hemorrhage.

Q: Is Algifor used for pain that is not related to inflammation?

A: Yes, the drug is officially indicated for the symptomatic relief of pain (analgesic effect), including types of pain that may not be directly caused by an underlying inflammatory condition.

Q: Are there different forms of Algifor (e.g., tablets, liquid)?

A: Yes, the drug is available for oral administration in several different forms. These typically include film-coated tablets, soft capsules, and oral liquid suspensions (syrup).

Q: Can taking Algifor cause me to feel dizzy?

A: Yes, official product labeling lists dizziness as a potential common adverse reaction that has been documented during the use of the drug.

Q: Does Algifor affect sleep?

A: Official documents list adverse reactions related to the nervous system, such as somnolence (drowsiness) or insomnia, though these are typically classified as uncommon reactions.

Q: Is Algifor known by different names in other countries?

A: Algifor is a specific brand name for the active ingredient Ibuprofen. This active substance is widely sold globally under numerous different brand names.

Q: Does Algifor contain caffeine?

A: Algifor, as a single-ingredient formulation, only contains Ibuprofen as its active substance and does not contain caffeine. However, combination products containing both ibuprofen and caffeine are available under different brand names.

Q: Can Algifor be bought without a prescription?

A: Yes, for certain specified strengths and package sizes, the drug is classified for over-the-counter (OTC) purchase and use without a prescription.

Q: Can Algifor affect my liver function?

A: The drug is metabolized in the liver, and while severe hepatic impairment is a contraindication, official documents note that the use of high doses may cause temporary elevations of liver enzyme levels.

Q: Is it normal to feel a bit nauseous after taking Algifor?

A: Yes, nausea is explicitly listed in official documents as a common adverse reaction associated with the use of the drug.

Q: Is the onset time faster if I take the liquid form of Algifor?

A: Official labeling primarily states the general onset time for oral administration. While liquid forms are often used for convenience or flexible dosing, the documented onset of action remains similar to other rapid-release oral forms.

Q: Can people with asthma generally use Algifor?

A: Patients with pre-existing asthma, particularly those with known hypersensitivity reactions to aspirin or other NSAIDs, face contraindications or are subject to restricted use that requires careful monitoring, according to official labeling.

Q: Does taking Algifor affect blood tests?

A: Official documents note that the use of high doses may cause temporary elevations of liver enzyme levels, which are measured in some standard blood tests.

Q: Are there any common foods that interact with Algifor?

A: No specific common foods are listed as strictly contraindicated in official labeling. The medicine is generally recommended to be taken with food or milk to reduce the potential for gastrointestinal irritation.

Q: Are there specific periods during pregnancy when Algifor is generally avoided?

A: Yes, use is strictly avoided and contraindicated during the third trimester of pregnancy, particularly after 20 weeks gestation, due to documented risks to the developing fetus.

Q: Is there an age limit for taking Algifor?

A: The lowest established age for use is 3 months for the oral liquid suspension. However, use in infants between 3 and 12 months of age is subject to specific regulatory conditions and generally requires the direction of a healthcare professional.

Q: Is Algifor known to cause drowsiness?

A: Drowsiness (somnolence) is listed in official documentation as a documented adverse reaction, though it is often classified as uncommon.

Q: Is it generally considered safe for people with kidney problems?

A: The drug is strictly contraindicated for individuals with severe renal (kidney) impairment. For those with mild-to-moderate kidney issues, official labeling notes that use is subject to restrictions and may require careful monitoring due to the documented risk of functional deterioration.

Official Storage and Disposal Requirements

Storage of Algifor (ibuprofen) must adhere to regulatory conditions to ensure product stability. The medicine is required to be stored at controlled room temperature, typically below 25 C to 30 C, and must not be frozen. Storage must protect the product from light and moisture, and it should be kept in its original container.

Constraint	Requirement
Child Safety	Keep out of the sight and reach of children.
Disposal Rule	Do not dispose of via household wastewater or trash.
Handling	Return unused or expired product to a designated pharmacy or waste collection point.

Liquid forms, such as oral suspension, must be kept tightly closed and may require discarding after a specific in-use stability period following opening.